The Cochlear Ltd (ASX: COH) share price is in focus today following a trading update that includes a reduction to the company’s FY26 underlying net profit guidance and softer implant demand in developed markets.
What did Cochlear report?
- Second half FY26 sales growth now expected at 2â6% in constant currency (CC)
- FY26 underlying net profit guidance reduced to $290â330 million (was $435â460 million)
- Revenue for cochlear implants in developed markets flat for the recent quarter in CC
- Services revenue up 13% in the third quarter (CC); Acoustics revenue up 11% (CC)
- Additional FY26 profit impacts of up to $10 million (provisions for Middle East receivables), $20 million (lower gross margin), $18â25 million (cost base reshaping), and $25 million (FX impact after tax)
What else do investors need to know?
Softer trading in developed markets is being driven by hospital capacity constraints and a decline in referrals from the hearing aid channel, especially in the US and parts of Europe. Cochlear also faces growing uncertainty in the Middle East, with potential order cancellations and delayed deliveries due to regional conflict.
On a positive note, the company’s services and acoustics segments continue to show strong revenue growth, aided by new product launches and an expanding installed base. Cochlear says it has a robust R&D pipeline and remains focused on investing in long-term growth, particularly in the adults and seniors segment.
What did Cochlear management say?
CEO and President Dig Howitt, said:
Addressing hearing loss in adults and seniors continues to be treated as a discretionary intervention, highlighting the importance of our strategy to medicalise hearing loss so that treatment is recognised as an important health priority.
We remain confident of our market leadership. We have seen strong adoption of the Nucleus® Nexa
System across the developed markets, with very positive customer feedback and a strong interest in exploring the system’s potential to further improve hearing outcomes. With contracting of the new system complete, market share has been improving.
What’s next for Cochlear?
Cochlear plans to accelerate investment in the adults and seniors market and reshape its cost base to enable further growth. This includes reallocating resources towards strengthening referral pathways, enhancing commercial execution, and ongoing R&D for product innovation.
Despite near-term challenges, management says the company is positioned for long-term sustainable growth with a broad technology pipeline, including next-generation and totally implantable cochlear implants in regulatory trials.
Cochlear share price snapshot
Over the past 12 months, Cochlear shares have declined 35%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 15% over the same period.
The post Cochlear cuts FY26 earnings outlook amid softer sales appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cochlear Limited right now?
Before you buy Cochlear Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Bank of Queensland half-year 2026: profit falls, dividend steady as revenue rises
- South32 lifts net cash and sets Brazil Alumina output record in March quarter
- Mercury NZ upgrades FY2026 EBITDAF guidance
- EBOS Group trims FY26 earnings guidance as fuel costs bite
- 5 things to watch on the ASX 200 on Wednesday
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.